Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nths for those who received modified FOLFOX-6, containing oxaliplatin.
  • Of the 51 patients in the FOLPI treatment arm, 75 percent achieved disease control (defined as complete response, partial response or stable disease); two patients with a complete response, nine patients with a partial response and 27 patients with stable disease. In the FOLFOX treatment arm of 50 patients, 76 percent achieved disease control; three patients with a complete response, 11 patients with a partial response and 24 patients with stable disease.
  • Only 29 percent of the patients who received FOLPI showed evidence of neurotoxicity compared with 60 percent of patients treated with FOLFOX. In addition, 16 percent of FOLFOX-treated patients exhibited severe (Grade 3/4) neurotoxicity, whereas no FOLPI-treated patients showed evidence of severe neurotoxicity. Three different measurements of neuropathy were statistically significant for FOLPI as a potential neuropathy-sparing alternative to FOLFOX (p<0.0019).
  • With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile neutropenia and no bleeding complications have been observed to date. In addition, 83 percent of the planned picoplatin dose of 150 mg/meter squared was able to be delivered monthly in the 51 patients treated in the FOLPI treatment arm of the trial.
  • Nonhematologic adverse events, including gastrointestinal toxicity, were similar between the treatment groups, with the exception of alopecia, which occurred more frequently with FOLPI.

    • "We continue to be encouraged by these interim, proof-of-concept Phase 2 safety and efficacy results, which suggest the potential of picoplatin in FOLPI as a neuropathy-sparing therapeutic alternative to the use of FOLFOX for the first-line treatment of metast
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
    2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
    3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
    5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
    6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
    7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
    8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
    9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
    10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
    11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
    (Date:5/17/2013)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... today announced that it will release its unaudited financial results ... on Tuesday, May 28, 2013.  The Company will host a ... EDT (May 28, 2013 at 8:00 p.m. China Standard Time) ... on recent corporate developments. To access the conference ...
    (Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
    Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
    (Date:5/19/2013)... 2013 Healthcare leaders will gather at ... the Walt Disney World Swan and Dolphin in Orlando, ... innovation, care delivery and healthcare reform and implementation. , ... healthcare markets, with consolidation, efficiency and reduced ... Todd Ebert, Amerinet president and CEO. “There is a ...
    (Date:5/19/2013)... The muscles in the human body are dependent ... the biggest and most significant nervous systems in the ... comprises of peripheral nerves that reside outside of the ... the limbs and hands, as well as other organs, ... due to trauma or physical injury, their functionality is ...
    (Date:5/19/2013)... These molecular diagnostics market reports ... Japan, Italy, Germany and France:, ... practice, as well as key economic, regulatory, demographic, ... during the next five years. ,     An ... test formats, detection methodologies, trends in testing automation ...
    (Date:5/19/2013)... (PRWEB) May 19, 2013 Farming methods ... seed in the ground 10,000 years ago. Most recently, ... farm productivity by using genetically engineered seeds and by ... seeing a backlash to these techniques due to the ... chemicals and a corresponding surge in interest in organic, ...
    (Date:5/19/2013)... Agora Health Limited developed by Rachael Linkie is ... how to increase memory power naturally and effectively. The ... people re-new their entire health from the inside out. It ... a fatigued mind. In addition, the program helps people keep ... The author claimed that this program can help people overcome ...
    Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
    ... Beauty Professionals Encouraged to Share Educational Materials , ... , WASHINGTON, July 23 Look ... to help women cope with the appearance-related changes of cancer treatment, today ... to generate awareness and increase program participation during its 20th anniversary year. ...
    ... , , Infusion ... LOUISVILLE, Ky., July 23 University of Louisville physicians performed the ... Louisville, KY, on July 17, 2009. The procedure is part of the ... disease. , , The first ...
    ... , SAN DIEGO, July 23 Orexigen Therapeutics, ... has priced an underwritten public offering of 10,000,000 shares of ... Net proceeds, after estimated underwriting discounts and commissions and estimated ... underwriter a 30-day option to purchase up to an additional ...
    ... July 23 Estimates place the prevalence of physical disabilities ... the global adult population according to THE ORTHOPAEDIC INDUSTRY ... , "Our sources indicate that ... 25 percent over the past ten years, and those conditions ...
    ... /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH.PK) ( http://www.mitcanada.ca ... that it has been granted a completely new, 8,000 ... from the "China Medical City" in Taizhou city for ... operation facility will harbor all the sub-assembly, final assembly ...
    ... , , , ... TELEHOUSE America ( www.telehouse.com ... Internet exchanges, and managed IT services, today announced it is offering ... loss prevention (DLP) consulting services as part of its ...
    Cached Medicine News:Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry 2Health News:MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 3Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 4
    ... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
    The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
    Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
    Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
    Medicine Products: